Nasus Pharma Ltd (NSRX) Form 424B5 — Sep 18, 2026
Nasus Pharma filed a 424B5 prospectus supplement on September 18, 2026 establishing an at-the-market equity program of up to $8,500,000 in ordinary shares through BTIG as sales agent. Sales will be made at prevailing market prices on NYSE American, where the stock last traded at $3.53, and BTIG earns a commission of up to 3% of gross proceeds. The Israeli clinical-stage biotech develops powder-based intranasal products led by NS002, an intranasal epinephrine for anaphylaxis, with a pivotal Phase 3 planned for the fourth quarter of 2026.
Key figures
- Cash Position
- 7818000
- Gross Proceeds
- 8500000
- Offering Price
- at-the-market sales at prevailing prices; last reported sale $3.53 on Sep 17, 2026; $3.65 assumed for illustrative purposes
- Shares Offered
- up to 2,328,767 shares if sold at assumed $3.65 (actual amount discretionary under ATM)
- Shares Outstanding
- 11713808
- Shelf Capacity
- 50000000
- Restricted Cash
- 86000
- Short Term Deposit
- 4000000
- Accumulated Deficit
- 24500000
- Sales Agent Commission
- up to 3.0% of gross proceeds
- Non Affiliate Market Value
- 26904184
- Total Shareholders Equity
- 10996000
- Legal Fee Reimbursement Cap
- 75000
- Estimated Offering Expenses
- 176905
- Net Tangible Book Value Per Share
- 0.94
- Shares Outstanding After Full Sale
- 14042575
- Total Cash Deposits And Restricted
- 11904000
- Adjusted Net Tangible Book Value Per Share
- 1.36
- Max Dilution Percent Of Shares Outstanding
- ~19.9% if fully sold at $3.65 (computed: 2,328,767 / 11,713,808)
- Immediate Dilution Per Share To New Investors
- 2.29
AI analysis
Red flags5 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.